BIAF 8-K: SEC filing

bioAffinity Technologies

Filed with the SEC on · accession 0001493152-26-052713

BIAF filed a 8-K (current report) with the SEC on Nov 17, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

bioAffinity Technologies announced that a record number of CyPath Lung tests were performed in October 2026, marking the highest monthly testing volume for its noninvasive lung cancer test.

Key details

RegistrantbioAffinity Technologies, Inc.
President and chief executive officerMaria Zannes

✦ Ask GOAX AI about this filing — what it means for BIAF, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BIAF?

Click here

Frequently asked questions

What did BIAF file with the SEC on Nov 17, 2026?

BIAF filed a 8-K (SEC filing). bioAffinity Technologies announced that a record number of CyPath Lung tests were performed in October 2026, marking the highest monthly testing volume for its noninvasive lung cancer test.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other BIAF SEC filings

Get alerts when BIAF files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days